Form 4: Boundless Bio Executive Neil Abdollahian Reprices Stock Options

Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., repriced several stock option grants on August 19, 2024, according to a Form 4 filing with the SEC.

Summary

• Neil Abdollahian, Chief Business Officer of Boundless Bio, Inc., filed a Form 4 with the SEC on August 20, 2024.
• The filing reports changes in beneficial ownership related to stock options.
• On August 19, 2024, Abdollahian repriced multiple stock option grants with an original exercise price of $4.1, $8.19, and $16 to a new exercise price of $3.56.
• The repriced options include 82,051 shares originally granted on August 9, 2022, 19,948 shares originally vesting monthly from January 6, 2022, 54,871 shares originally vesting monthly from July 13, 2023, 36,852 shares originally vesting monthly from March 15, 2024, and 23,191 shares originally vesting monthly from April 27, 2024.
• The repricing does not change other terms of the options, except that the exercise price will revert to the original price if the option is exercised or employment is terminated before August 19, 2026, due to a change in control, or a qualifying termination.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The repricing of stock options is a common practice, but the conditional nature adds some complexity. It's neither overwhelmingly positive nor negative.

Positives

• The repricing of stock options could incentivize the executive to remain with the company.
• The new exercise price of $3.56 reflects the fair market value of the common stock on the date of repricing.

Negatives

• The repricing may dilute existing shareholders if the options are exercised at the lower price.
• The conditional nature of the repricing adds complexity to the option terms.

Risks

• The original exercise price could be reinstated if the executive's employment is terminated before the premium end date under certain conditions.
• A change in control could also trigger the reinstatement of the original exercise price.

Future Outlook

The exercise price of the options may revert to the original price under certain conditions before August 19, 2026, including a change in control or a non-qualifying termination of employment.

Industry Context

Stock option repricing is a common practice to incentivize employees, especially when the stock price has declined. It aims to keep employees motivated and aligned with the company's long-term success.

Comparison to Industry Standards

• Stock option repricing is a fairly common practice in the biotech industry, especially for companies that have seen their stock price decline.
• Many companies, such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, use stock options as part of their executive compensation packages.
• The specific terms of the repricing, such as the conditions for reverting to the original exercise price, are company-specific and depend on factors like the company's performance and the executive's role.

Stakeholder Impact

• Shareholders may experience dilution if the options are exercised at the lower price.
• The repricing aims to incentivize the Chief Business Officer, potentially benefiting the company's performance.

Key Dates